STAT+: Medicare Is Spending Far Less than Expected on New Alzheimer’s Drugs

Why It Matters

The shortfall reshapes Medicare’s drug‑budget outlook and signals caution for manufacturers betting on high‑cost specialty Alzheimer’s treatments. It also underscores the need for more practical, effective therapies to meet a growing elderly market.

Key Takeaways

• Medicare expects negligible spending on Leqembi and Kisunla through 2027
• IV administration and imaging requirements hinder patient adoption
• Eligible patient pool remains small due to strict diagnostic criteria
• Clinical benefits modest; risk of brain bleeding persists
• Initial projections of billions in annual costs proved unrealistic

Pulse Analysis

The FDA’s recent approval of Leqembi (lecanemab) and Kisunla (donanemab) sparked optimism that disease‑modifying Alzheimer’s drugs could finally curb the nation’s escalating dementia costs. Payers, especially Medicare, built budget models around projected billions in annual expenditures, assuming rapid market penetration among the roughly six million Medicare beneficiaries with early‑stage Alzheimer’s. Those forecasts, however, rested on clinical trial efficacy rather than the logistical realities of delivering intravenous biologics in a fragmented outpatient setting.

In practice, the infusion‑centric administration of both agents demands specialized infusion centers, repeated magnetic resonance imaging, and close monitoring for amyloid‑related imaging abnormalities. Such requirements raise both direct costs and patient burden, narrowing the eligible pool to those with confirmed amyloid pathology and sufficient vascular health. Neurologists also point to modest cognitive gains that often fall short of patients’ expectations, while the FDA label warns of a heightened risk of cerebral microhemorrhage. These clinical and operational hurdles have translated into a muted prescribing pattern, prompting CMS to slash its spending outlook for the next two fiscal years.

The divergence between projected and actual utilization carries broader implications for the biotech sector and health‑policy makers. Investors may recalibrate valuations of companies banking on high‑price, low‑volume specialty drugs, while insurers could tighten prior‑authorization criteria or negotiate risk‑sharing agreements. For policymakers, the episode highlights the importance of aligning reimbursement incentives with real‑world effectiveness and delivery feasibility. Future Alzheimer’s therapeutics will likely need to demonstrate not only disease‑modifying potency but also streamlined administration pathways to achieve meaningful market uptake.